Success achieved with the first-in-class oral anti-cancer drug, Inobrodib, by CellCentric and Sygnature Discovery.

An integrated project team at Sygnature Discovery worked collaboratively to design, synthesise, and support the pre-clinical development of Inobrodib, a new, first-in-class oral anti-cancer drug being developed by CellCentric. What are Androgens? Androgens are ‘male hormones’ including testosterone and…

Continue ReadingSuccess achieved with the first-in-class oral anti-cancer drug, Inobrodib, by CellCentric and Sygnature Discovery.